Vimarsana
Biggest News Aggregation in the World

Page 5 - Berkeley Catalyst Fund News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Berkeley Catalyst Fund. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Berkeley Catalyst Fund Today - Breaking & Trending Today

Inhalon Biopharma Receives $7 Million from USAMRDC to Study Inhaled "Muco-trapping" Antibody for the Treatment of COVID-19 - Vimarsana News

Inhalon Biopharma Receives $7 Million from USAMRDC to Study Inhaled "Muco-trapping" Antibody for the Treatment of COVID-19

/PRNewswire/ -- Inhalon Biopharma, a start-up immunotherapy company developing an inhaled "muco-trapping" antibody platform for treating a variety of acute...

D. One Vision Management Leads $16 Million Series A Investment In PrinterPrezz - Vimarsana News

D. One Vision Management Leads $16 Million Series A Investment In PrinterPrezz

Press release content from Business Wire. The AP news staff was not involved in its creation. D. One Vision Management Leads $16 Million Series A Investment In PrinterPrezz December 10, 2020 GMT NEW YORK--(BUSINESS WIRE)--Dec 10, 2020-- D. One Vision Management with its DOV Singularity Fund, an alternative investment vehicle for investors seeking growth and diversification in tech-empowered future, today announced the addition of PrinterPrezz, the first Medifacturing TM company in the world to its investment portfolio. Through its DOV Singularity Fund, D. One Vision Management served as the l...

Source: apnews.com
PrinterPrezz Completes $16M Series A Funding - Vimarsana News

PrinterPrezz Completes $16M Series A Funding

PrinterPrezz, a CA-based Medifacturing company, completed $16m Series A funding. The round was led by D. One Vision Management with participation from Boutique Venture Partners, Berkeley Catalyst Fund while Solvay Ventures served as strategic investor. Led by Shri Shetty, CEO, PrinterPrezz combines additive manufacturing technology platforms, nanotechnologies and surgical expertise to develop next generation medical devices from concept and design through FDA approval and volume production. Committed to ongoing compliance with ISO13485:2016 and all relevant regulatory requirements including...